{
    "2018-08-03": [
        [
            {
                "time": "2018-01-03",
                "original_text": "Avoid Treating Biogen Like a Speculative Drug Stock",
                "features": {
                    "keywords": [
                        "Biogen",
                        "Speculative",
                        "Drug",
                        "Stock"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-04",
                "original_text": "Teva Chief Says Generic Prices Are Improving — Will Its Stock Also Do So?",
                "features": {
                    "keywords": [
                        "Teva",
                        "Generic",
                        "Prices",
                        "Improving",
                        "Stock"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-05",
                "original_text": "bluebird (BLUE) Q2 Loss Wider Than Expected, Revenues Miss",
                "features": {
                    "keywords": [
                        "bluebird",
                        "Q2",
                        "Loss",
                        "Wider",
                        "Revenues",
                        "Miss"
                    ],
                    "sentiment_score": -0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "biotechnology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-01-06",
                "original_text": "Aduro (ADRO) Q2 Loss Narrower Than Expected, Revenues Miss",
                "features": {
                    "keywords": [
                        "Aduro",
                        "Q2",
                        "Loss",
                        "Narrower",
                        "Revenues",
                        "Miss"
                    ],
                    "sentiment_score": -0.4,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "biotechnology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-01-07",
                "original_text": "Teva (TEVA) Q2 Earnings Beat, Revenues Miss, Stock Down",
                "features": {
                    "keywords": [
                        "Teva",
                        "Q2",
                        "Earnings",
                        "Beat",
                        "Revenues",
                        "Miss",
                        "Stock",
                        "Down"
                    ],
                    "sentiment_score": -0.3,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-01-08",
                "original_text": "Pharma Stock Roundup: PFE Dominates Headlines, BMY Drug Gets EU Approval",
                "features": {
                    "keywords": [
                        "Pharma",
                        "Stock",
                        "PFE",
                        "BMY",
                        "EU",
                        "Approval"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-09",
                "original_text": "The Swiss Stock Market Finished With A Slight Increase",
                "features": {
                    "keywords": [
                        "Swiss",
                        "Stock",
                        "Market",
                        "Slight",
                        "Increase"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "market"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-10",
                "original_text": "Eli Lilly’s Q2 2018 Earnings: New Products",
                "features": {
                    "keywords": [
                        "Eli",
                        "Lilly",
                        "Q2",
                        "2018",
                        "Earnings",
                        "New",
                        "Products"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}